Last year the large NHLBI FREEDOM trial demonstrated that bypass surgery was superior to PCI when treating diabetic patients who have multivessel coronary disease. CABG resulted in significant reductions in death and MI, but this was offset slightly by a higher rate of stroke in the CABG group. Now a new report from FREEDOM published in JAMA suggests that…
New Insights Into Surgery Versus Stents For Diabetics With Multivessel Disease
October 17, 2013 by Leave a Comment
A Disruptive TASTE of the Future? Getting the Best of Randomized Trials AND Observational Studies
September 1, 2013 by Leave a Comment
A new study from Scandanavia may influence the treatment of acute myocardial infarction. But it also may end up having a much bigger impact on the entire field of medicine by pointing the way to an entirely new way of performing randomized clinical trials rapidly and inexpensively. One expert said the trial design may represent…
Dramatic Increase in Use of Radial Artery Access for PCI in the U.S.
June 10, 2013 by Leave a Comment
In the last six years interventional cardiologists have dramatically increased their use of radial access for PCI, according to a retrospective study published in Circulation. Using data from the CathPCI registry on more than 2.8 million procedures between January 2007 and September 2012, Dmitriy Feldman and colleagues found that radial access PCI increased 13-fold, from a negligible 1.2% at the beginning of the study…
Should Radial Artery Access Be The Default Choice For PCI?
February 7, 2013 by Leave a Comment
Over on CardioExchange six cardiologists, from fellows to senior faculty, talk about whether radial artery access should be the “default choice for PCI: Megan Coylewright, MD, MPH (interventional fellow, Mayo Clinic): …radial PCI should be a part of every interventionalist’s toolkit… Micah Eimer, MD (cardiologist, Glenview, IL): The data are pretty convincing on the lower rate of…
Early Results: Antiplatelet Drug Cangrelor Appears Effective For PCI
January 8, 2013 by Leave a Comment
The experimental antiplatelet drug cangrelor was superior to traditional clopidogrel in reducing ischemic events at 48 hours in PCI patients, according to the Medicines Company, which is developing the drug. The company today announced positive results from the phase 3 CHAMPION PHOENIX trial, a randomized, double-blind study comparing intravenous cangrelor to oral clopidogrel in PCI patients. The…
Recent Comments